GSK’s RSV vaccine shows long-term efficacy in late-stage trial

This post was originally published on this site

The British drugmaker said a ‘Phase III’ trial showed vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions.

GSK’s shot, called Arexvy is designed to protect people aged 60 and over from RSV, which typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.

European regulators approved the shot earlier this month for the disease which causes thousands of hospitalisations and deaths annually.